Residual risk for secondary ischemic events in patients with atherothrombotic disease: Opportunity for future improvements in patient care

References

• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329–39.
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.
   PubMed Web of Science ®Google Scholar
• Kris-Etherton P, Eckel RH, Howard BV, St Jeor S, Bazzarre TL. AHA Science Advisory: Lyon Diet Heart Study. Benefits of a Mediterranean-style, National Cholesterol Education Program/American Heart Association Step I Dietary Pattern on Cardiovascular Disease. Circulation. 2001;103:1823–5.
   PubMed Web of Science ®Google Scholar
• Lee KW, Lip GY. Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review. Arch Intern Med. 2003;163:2368–92.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, . Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353:2111–20.
   PubMed Web of Science ®Google Scholar
• Ferguson JJ. The role of oral antiplatelet agents in atherothrombotic disease. Am J Cardiovasc Drugs. 2006;6:149–57.
   PubMedGoogle Scholar
• Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, . Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25–146.
   PubMed Web of Science ®Google Scholar
• Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, . Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation. 2006;113:e409–49.
   PubMed Web of Science ®Google Scholar
• Allison MA, Ho E, Denenberg JO, Langer RD, Newman AB, Fabsitz RR, . Ethnic-specific prevalence of peripheral arterial disease in the United States. Am J Prev Med. 2007;32:328–33.
   PubMed Web of Science ®Google Scholar
• Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation. 2004;110:738–43.
   PubMed Web of Science ®Google Scholar
• Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, . Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381–6.
   PubMed Web of Science ®Google Scholar
• Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, . ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113:e463–654.
   PubMed Web of Science ®Google Scholar
• Howell MA, Colgan MP, Seeger RW, Ramsey DE, Sumner DS. Relationship of severity of lower limb peripheral vascular disease to mortality and morbidity: a six-year follow-up study. J Vasc Surg. 1989;9:691–6; discussion 6–7.
   PubMed Web of Science ®Google Scholar
• McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis. 1991;87:119–28.
   PubMed Web of Science ®Google Scholar
• McDermott MM, Feinglass J, Slavensky R, Pearce WH. The ankle-brachial index as a predictor of survival in patients with peripheral vascular disease. J Gen Intern Med. 1994;9:445–9.
   PubMed Web of Science ®Google Scholar
• Hirsh J, O'Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin: current and future advances. Circulation. 2007;116:552–60.
   PubMed Web of Science ®Google Scholar
• Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, Housley E, . Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1996;25:1172–81.
   PubMed Web of Science ®Google Scholar
• McDermott MM, Liu K, Greenland P, Guralnik JM, Criqui MH, Chan C, . Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA. 2004;292:453–61.
   PubMed Web of Science ®Google Scholar
• Wasserman EJ, Shipley NM. Atherothrombosis in acute coronary syndromes: mechanisms, markers, and mediators of vulnerability. Mt Sinai J Med. 2006;73:431–9.
   PubMed Web of Science ®Google Scholar
• Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111:3481–8.
   PubMed Web of Science ®Google Scholar
• Napoli C, D'Armiento FP, Mancini FP, Postiglione A, Witztum JL, Palumbo G, . Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest. 1997;100:2680–90.
   PubMed Web of Science ®Google Scholar
• Napoli C, de Nigris F, Welch JS, Calara FB, Stuart RO, Glass CK, . Maternal hypercholesterolemia during pregnancy promotes early atherogenesis in LDL receptor-deficient mice and alters aortic gene expression determined by microarray. Circulation. 2002;105:1360–7.
   PubMed Web of Science ®Google Scholar
• Napoli C, Witztum JL, de Nigris F, Palumbo G, D'Armiento FP, Palinski W. Intracranial arteries of human fetuses are more resistant to hypercholesterolemia-induced fatty streak formation than extracranial arteries. Circulation. 1999;99:2003–10.
   PubMed Web of Science ®Google Scholar
• Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482–94.
   PubMed Web of Science ®Google Scholar
• Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20:1262–75.
   PubMed Web of Science ®Google Scholar
• Sakariassen KS, Nievelstein PF, Coller BS, Sixma JJ. The role of platelet membrane glycoproteins Ib and IIb-IIIa in platelet adherence to human artery subendothelium. Br J Haematol. 1986;63:681–91.
   PubMed Web of Science ®Google Scholar
• Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol. 2008;28:403–12.
   PubMed Web of Science ®Google Scholar
• Brass LF. Thrombin and platelet activation. Chest. 2003;124:Suppl:18–25S.
   PubMedGoogle Scholar
• Kulkarni S, Dopheide SM, Yap CL, Ravanat C, Freund M, Mangin P, . A revised model of platelet aggregation. J Clin Invest. 2000;105:783–91.
   PubMed Web of Science ®Google Scholar
• Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115:3378–84.
   PubMed Web of Science ®Google Scholar
• May AE, Seizer P, Gawaz M. Platelets: inflammatory firebugs of vascular walls. Arterioscler Thromb Vasc Biol. 2008;28:s5–10.
   PubMed Web of Science ®Google Scholar
• Krotz F, Sohn HY, Gloe T, Zahler S, Riexinger T, Schiele TM, . NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood. 2002;100:917–24.
   PubMed Web of Science ®Google Scholar
• Cognasse F, Hamzeh H, Chavarin P, Acquart S, Genin C, Garraud O. Evidence of Toll-like receptor molecules on human platelets. Immunol Cell Biol. 2005;83:196–8.
   PubMed Web of Science ®Google Scholar
• Satoh M, Ishikawa Y, Minami Y, Takahashi Y, Nakamura M. Role of Toll like receptor signaling pathway in ischemic coronary artery disease. Front Biosci. 2008;13:6708–15.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, . Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52.
   PubMed Web of Science ®Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.
   PubMed Web of Science ®Google Scholar
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349–57.
   PubMed Web of Science ®Google Scholar
• Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, . High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549–59.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, Mc Cabe CH, Rader DJ, Rouleau JL, Belder R, . Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–504.
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, . Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307–16.
   PubMed Web of Science ®Google Scholar
• Gissi HFI, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, . Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1231–9.
   PubMed Web of Science ®Google Scholar
• Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, . Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248–61.
   PubMed Web of Science ®Google Scholar
• La Rosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, . Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–35.
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, . High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437–45.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto A, Jr, Kastelein JJ, . Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001–9.
   PubMed Web of Science ®Google Scholar
• Waters DD, La Rosa JC, Barter P, Fruchart JC, Gotto A Jr, Carter R, . Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol. 2006;48:1793–9.
   PubMed Web of Science ®Google Scholar
• Levy WC. Observational studies of statins in systolic heart failure. Heart Fail Clin. 2008;4:201–8.
   PubMedGoogle Scholar
• Stypmann J, Schubert A, Welp H, Schulte H, Assmann G, Breithardt G, . Atorvastatin therapy is associated with reduced levels of N-terminal prohormone brain natriuretic peptide and improved cardiac function in patients with heart failure. Clin Cardiol. 2008;31:478–81.
   PubMed Web of Science ®Google Scholar
• Vrtovec B, Okrajsek R, Golicnik A, Ferjan M, Starc V, Schlegel TT, . Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure. J Card Fail. 2008;14:140–4.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438–45.
   PubMed Web of Science ®Google Scholar
• O'Regan C, Wu P, Arora P, Perri D, Mills EJ. Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. Am J Med. 2008;121:24–33.
   PubMed Web of Science ®Google Scholar
• Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev. 2007(4): CD000123.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, . Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992;340:1173–8.
   PubMed Web of Science ®Google Scholar
• Pitt B, O'Neill B, Feldman R, Ferrari R, Schwartz L, Mudra H, . The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol. 2001;87:1058–63.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–53.
   PubMed Web of Science ®Google Scholar
• Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782–8.
   PubMed Web of Science ®Google Scholar
• Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, . Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351:2058–68.
   PubMed Web of Science ®Google Scholar
• Saha SA, Molnar J, Arora RR. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials. J Cardiovasc Pharmacol Ther. 2007;12:192–204.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, . Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174–83.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, . Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–59.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, . Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:1225–37.
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033–41.
   PubMed Web of Science ®Google Scholar
• Smith S, Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, . AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113:2363–72.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008;359:1565–76.
   PubMed Web of Science ®Google Scholar
• Patel A, Mac Mahon S, Chalmers J, Neal B, Billot L, Woodward M, . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP, Goff DC, Jr, Bigger JT, Buse JB, . Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.
   PubMed Web of Science ®Google Scholar
• Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, . Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1622–32.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Wetterslev J, Pranesh S, Sawhney S, Gluud C, Messerli FH. Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis. Lancet. 2008;372:1962–76.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol. 2008;52:1482–9.
   PubMed Web of Science ®Google Scholar
• Campbell DJ, Aggarwal A, Esler M, Kaye D. beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure. Lancet. 2001;358:1609–10.
   PubMed Web of Science ®Google Scholar
• Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Jr, . ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50:e1–157.
   PubMed Web of Science ®Google Scholar
• Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Lancet. 1997;350:389–96.
   PubMed Web of Science ®Google Scholar
• Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation. 2002;105:557–63.
   PubMed Web of Science ®Google Scholar
• Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, . A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:1444–51.
   PubMed Web of Science ®Google Scholar
• Anand S, Yusuf S, Xie C, Pogue J, Eikelboom J, Budaj A, . Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007;357:217–27.
   PubMed Web of Science ®Google Scholar
• A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Ann Neurol. 1997;42:857–65.
   PubMed Web of Science ®Google Scholar
• Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med. 2005;143:241–50.
   PubMed Web of Science ®Google Scholar
• Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J. 2008;29:155–65.
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Hernandez-Diaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol. 2001;52:563–71.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, . Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–17.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, . Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982–8.
   PubMed Web of Science ®Google Scholar
• Persantine Aspirin Trial in cerebral ischemia. Part II: Endpoint results. The American-Canadian Co-Operative Study group. Stroke. 1985;16:406–15.
   PubMedGoogle Scholar
• The European Stroke Prevention Study (ESPS). Principal end-points. The ESPS Group. Lancet. 1987;2:1351–4.
   PubMed Web of Science ®Google Scholar
• Bousser MG, Eschwege E, Haguenau M, Lefaucconnier JM, Thibult N, Touboul D, . ‘AICLA’ controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke. 1983;14:5–14.
   PubMed Web of Science ®Google Scholar
• Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1–13.
   PubMed Web of Science ®Google Scholar
• Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367:1665–73.
   PubMed Web of Science ®Google Scholar
• Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, . Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238–51.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, . Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360:2066–78.
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, . Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356:1620–30.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, . Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304–16.
   PubMed Web of Science ®Google Scholar
• Tardif JC, Gregoire J, L'Allier PL, Anderson TJ, Bertrand O, Reeves F, . Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation. 2004;110:3372–7.
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, . Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431–43.
   PubMed Web of Science ®Google Scholar
• Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, . Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet. 2007;370:1907–14.
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512–7.
   PubMed Web of Science ®Google Scholar
• Crouse J, 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, . Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297:1344–53.
   PubMed Web of Science ®Google Scholar
• Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001;357:577–81.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, . Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–22.
   PubMed Web of Science ®Google Scholar
• Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin ‘resistance’ and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008;336:195–8.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, . Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49:1505–16.
   PubMed Web of Science ®Google Scholar
• Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, . Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373:309–17.
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, . Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354–62.
   PubMed Web of Science ®Google Scholar
• Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, . Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363–75.
   PubMed Web of Science ®Google Scholar
• Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, . Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27:1166–73.
   PubMed Web of Science ®Google Scholar
• Brown TM, Bittner V. Biomarkers of atherosclerosis: clinical applications. Curr Cardiol Rep. 2008;10:497–504.
   PubMedGoogle Scholar
• Catella F, Healy D, Lawson JA, Fitz Gerald GA. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci U S A. 1986;83:5861–5.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650–5.
   PubMed Web of Science ®Google Scholar
• Budoff MJ, Gul KM. Expert review on coronary calcium. Vasc Health Risk Manag. 2008;4:315–24.
   PubMedGoogle Scholar
• Anand DV, Lim E, Hopkins D, Corder R, Shaw LJ, Sharp P, . Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. Eur Heart J. 2006;27:713–21.
   PubMed Web of Science ®Google Scholar
• Arad Y, Goodman KJ, Roth M, Newstein D, Guerci AD. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. J Am Coll Cardiol. 2005;46:158–65.
   PubMed Web of Science ®Google Scholar
• Raggi P, Cooil B, Shaw LJ, Aboulhson J, Takasu J, Budoff M, . Progression of coronary calcium on serial electron beam tomographic scanning is greater in patients with future myocardial infarction. Am J Cardiol. 2003;92:827–9.
   PubMed Web of Science ®Google Scholar
• Shaw LJ, Raggi P, Schisterman E, Berman DS, Callister TQ. Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality. Radiology. 2003;228:826–33.
   PubMed Web of Science ®Google Scholar
• Vliegenthart R, Oudkerk M, Song B, van der Kuip DA, Hofman A, Witteman JC. Coronary calcification detected by electron-beam computed tomography and myocardial infarction. The Rotterdam Coronary Calcification Study. Eur Heart J. 2002;23:1596–603.
   PubMedGoogle Scholar
• Georgiou D, Budoff MJ, Kaufer E, Kennedy JM, Lu B, Brundage BH. Screening patients with chest pain in the emergency department using electron beam tomography: a follow-up study. J Am Coll Cardiol. 2001;38:105–10.
   PubMed Web of Science ®Google Scholar
• Keelan PC, Bielak LF, Ashai K, Jamjoum LS, Denktas AE, Rumberger JA, . Long-term prognostic value of coronary calcification detected by electron-beam computed tomography in patients undergoing coronary angiography. Circulation. 2001;104:412–7.
   PubMed Web of Science ®Google Scholar
• Greenland P, Bonow RO, Brundage BH, Budoff MJ, Eisenberg MJ, Grundy SM, . ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000125 Expert Consensus Document on Electron Beam Computed Tomography). Circulation. 2007;115:402–26.
   PubMed Web of Science ®Google Scholar
• Laurent S, Boutouyrie P. Arterial stiffness: a new surrogate end point for cardiovascular disease? J Nephrol. 2007;20:(Suppl 12):S45–50.
   PubMedGoogle Scholar
• Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation. 1999;99:2434–9.
   PubMed Web of Science ®Google Scholar
• Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation. 2002;106:2085–90.
   PubMed Web of Science ®Google Scholar
• Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, . Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37:1236–41.
   PubMed Web of Science ®Google Scholar
• Laurent S, Katsahian S, Fassot C, Tropeano AI, Gautier I, Laloux B, . Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke. 2003;34:1203–6.
   PubMed Web of Science ®Google Scholar
• Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML, Schalekamp MA, . Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation. 2006;113:657–63.
   PubMed Web of Science ®Google Scholar
• Sutton-Tyrrell K, Najjar SS, Boudreau RM, Venkitachalam L, Kupelian V, Simonsick EM, . Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation. 2005;111:3384–90.
   PubMed Web of Science ®Google Scholar
• Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, . Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation. 2006;113:664–70.
   PubMed Web of Science ®Google Scholar
• Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation. 2001;103:987–92.
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Schmieder RE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens. 2008;21:500–8.
   PubMed Web of Science ®Google Scholar
• Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41–6.
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–43.
   PubMed Web of Science ®Google Scholar
• Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, . Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005;111:570–5.
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Hislop C, McConnell D, Elliott M, Stasiv Y, Wang N, . Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial. Lancet. 2009;373:649–58.
   PubMed Web of Science ®Google Scholar
• Serruys PW, Garcia-Garcia HM, Buszman P, Erne P, Verheye S, Aschermann M, . Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 2008;118:1172–82.
   PubMed Web of Science ®Google Scholar
• The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial (STABILITY). NCT00799903. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00799903 (accessed 26 February 2009).
   Google Scholar
• FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes. NCT00743925. Available at: //www.clinicaltrials.gov/ct2/show/NCT00743925 (accessed 26 February 2009).
   Google Scholar
• Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007;49:2129–38.
   PubMed Web of Science ®Google Scholar
• Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon R, 3rd, Criqui M, . Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511.
   PubMed Web of Science ®Google Scholar
• Steg PG, Bhatt DL, Wilson PW, D'Agostino R, SrOhman EM, Rother J, . One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197–206.
   PubMed Web of Science ®Google Scholar